Keyphrases
Anticoagulation
25%
Antithrombotic Therapy
100%
Apixaban
25%
Appropriate Dose
25%
Atrial Fibrillation
100%
Bleeding Risk
25%
Chronic Kidney Disease
100%
Dabigatran
25%
Direct Oral Anticoagulants
75%
Dose Adjustment
25%
Edoxaban
25%
Embolism
25%
Hemodialysis
25%
Ischemic Stroke
50%
Kidney Disease Progression
75%
Low Risk
25%
Major Bleeding
75%
Moderate Chronic Kidney Disease
25%
Non-valvular Atrial Fibrillation
25%
Randomized Controlled Trial
25%
Risk of Ischemic Stroke
25%
Systemic Embolism
50%
Thromboembolism
25%
Twice Daily
25%
Warfarin
100%
Pharmacology, Toxicology and Pharmaceutical Science
Antithrombotic Therapy
100%
Apixaban
12%
Atrial Fibrillation
100%
Bleeding
25%
Brain Ischemia
37%
Chronic Kidney Failure
100%
Dabigatran
12%
Direct Oral Anticoagulant
37%
Edoxaban
12%
Hemodialysis
12%
Randomized Controlled Trial
12%
Thromboembolism
12%
Warfarin
50%